Zydus Lifesciences Limited (ZYDUSLIFE) - Net Assets

Latest as of September 2025: Rs280.90 Billion INR ≈ $3.04 Billion USD

Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) has net assets worth Rs280.90 Billion INR (≈ $3.04 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs468.97 Billion ≈ $5.07 Billion USD) and total liabilities (Rs188.07 Billion ≈ $2.03 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Zydus Lifesciences Limited for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs280.90 Billion
% of Total Assets	59.9%
Annual Growth Rate	20.38%
5-Year Change	76.55%
10-Year Change	380.35%
Growth Volatility	8.84

Zydus Lifesciences Limited - Net Assets Trend (2004–2025)

This chart illustrates how Zydus Lifesciences Limited's net assets have evolved over time, based on quarterly financial data. Check tangible net worth ratio of Zydus Lifesciences Limited to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Zydus Lifesciences Limited (2004–2025)

The table below shows the annual net assets of Zydus Lifesciences Limited from 2004 to 2025. For live valuation and market cap data, see ZYDUSLIFE company net worth.

Year	Net Assets	Change
2025-03-31	Rs263.58 Billion ≈ $2.85 Billion	+19.26%
2024-03-31	Rs221.02 Billion ≈ $2.39 Billion	+12.26%
2023-03-31	Rs196.88 Billion ≈ $2.13 Billion	+3.33%
2022-03-31	Rs190.54 Billion ≈ $2.06 Billion	+27.62%
2021-03-31	Rs149.30 Billion ≈ $1.61 Billion	+27.49%
2020-03-31	Rs117.10 Billion ≈ $1.27 Billion	+0.27%
2019-03-31	Rs116.79 Billion ≈ $1.26 Billion	+30.71%
2018-03-31	Rs89.36 Billion ≈ $966.34 Million	+25.57%
2017-03-31	Rs71.16 Billion ≈ $769.58 Million	+29.68%
2016-03-31	Rs54.87 Billion ≈ $593.43 Million	+24.13%
2015-03-31	Rs44.20 Billion ≈ $478.06 Million	+23.36%
2014-03-31	Rs35.83 Billion ≈ $387.52 Million	+16.96%
2013-03-31	Rs30.64 Billion ≈ $331.34 Million	+15.01%
2012-03-31	Rs26.64 Billion ≈ $288.10 Million	+19.01%
2011-03-31	Rs22.38 Billion ≈ $242.07 Million	+34.22%
2010-03-31	Rs16.68 Billion ≈ $180.36 Million	+32.57%
2009-03-31	Rs12.58 Billion ≈ $136.05 Million	+16.31%
2008-03-31	Rs10.82 Billion ≈ $116.97 Million	+22.95%
2007-03-31	Rs8.80 Billion ≈ $95.14 Million	+25.74%
2006-03-31	Rs7.00 Billion ≈ $75.66 Million	+17.90%
2005-03-31	Rs5.93 Billion ≈ $64.17 Million	+10.63%
2004-03-31	Rs5.36 Billion ≈ $58.01 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zydus Lifesciences Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 34342.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs247.99 Billion	103.53%
Common Stock	Rs1.01 Billion	0.42%
Other Comprehensive Income	Rs-9.46 Billion	-3.95%
Total Equity	Rs239.53 Billion	100.00%

Zydus Lifesciences Limited Competitors by Market Cap

The table below lists competitors of Zydus Lifesciences Limited ranked by their market capitalization.

Company	Market Cap
Postal Savings Bank of China Co Ltd F:3YB	$12.47 Billion
TURKIYE GARANTI BANKASI AS F:GBKB	$12.47 Billion
Indian Railway Finance Corporation Limited NSE:IRFC	$12.48 Billion
Penumbra Inc NYSE:PEN	$12.48 Billion
Lupin Limited NSE:LUPIN	$12.43 Billion
Washington H Soul Pattinson & Company Ltd AU:SOL	$12.42 Billion
United States Steel Corporation NYSE:X	$12.42 Billion
WILMAR INTL ADR/10 SD-50 F:RTH	$12.42 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zydus Lifesciences Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 198,295,000,000 to 239,531,000,000, a change of 41,236,000,000 (20.8%).
Net income of 45,255,000,000 contributed positively to equity growth.
Dividend payments of 3,025,000,000 reduced retained earnings.
Other comprehensive income decreased equity by 690,000,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs45.26 Billion	+18.89%
Dividends Paid	Rs3.02 Billion	-1.26%
Other Comprehensive Income	Rs-690.00 Million	-0.29%
Other Changes	Rs-304.00 Million	-0.13%
Total Change	Rs-	20.80%

Book Value vs Market Value Analysis

This analysis compares Zydus Lifesciences Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 4.80x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 100.38x to 4.80x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs11.39	Rs1143.10	x
2005-03-31	Rs12.60	Rs1143.10	x
2006-03-31	Rs7.42	Rs1143.10	x
2007-03-31	Rs9.19	Rs1143.10	x
2008-03-31	Rs11.27	Rs1143.10	x
2009-03-31	Rs12.07	Rs1143.10	x
2010-03-31	Rs15.91	Rs1143.10	x
2011-03-31	Rs21.21	Rs1143.10	x
2012-03-31	Rs25.14	Rs1143.10	x
2013-03-31	Rs28.76	Rs1143.10	x
2014-03-31	Rs33.59	Rs1143.10	x
2015-03-31	Rs41.53	Rs1143.10	x
2016-03-31	Rs52.28	Rs1143.10	x
2017-03-31	Rs67.99	Rs1143.10	x
2018-03-31	Rs85.42	Rs1143.10	x
2019-03-31	Rs101.45	Rs1143.10	x
2020-03-31	Rs101.35	Rs1143.10	x
2021-03-31	Rs126.91	Rs1143.10	x
2022-03-31	Rs166.05	Rs1143.10	x
2023-03-31	Rs172.46	Rs1143.10	x
2024-03-31	Rs195.96	Rs1143.10	x
2025-03-31	Rs238.02	Rs1143.10	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zydus Lifesciences Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 18.89%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 19.47%
• Asset Turnover: 0.62x
• Equity Multiplier: 1.55x
Recent ROE (18.89%) is below the historical average (22.91%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	24.81%	11.13%	0.89x	2.50x	Rs794.60 Million
2005	20.48%	9.77%	0.91x	2.29x	Rs621.60 Million
2006	21.81%	10.54%	0.92x	2.25x	Rs825.10 Million
2007	27.01%	13.09%	0.89x	2.32x	Rs1.47 Billion
2008	24.25%	11.37%	0.88x	2.42x	Rs1.51 Billion
2009	24.54%	10.59%	0.85x	2.74x	Rs1.80 Billion
2010	31.02%	13.70%	0.99x	2.30x	Rs3.42 Billion
2011	32.74%	15.92%	0.98x	2.10x	Rs4.94 Billion
2012	25.36%	12.82%	0.80x	2.48x	Rs3.95 Billion
2013	22.19%	10.35%	0.86x	2.50x	Rs3.59 Billion
2014	23.37%	11.16%	0.90x	2.32x	Rs4.60 Billion
2015	27.06%	13.30%	0.96x	2.13x	Rs7.25 Billion
2016	36.13%	20.51%	0.94x	1.87x	Rs13.99 Billion
2017	21.38%	15.87%	0.62x	2.19x	Rs7.92 Billion
2018	20.31%	14.92%	0.66x	2.07x	Rs9.01 Billion
2019	17.80%	14.04%	0.56x	2.26x	Rs8.10 Billion
2020	11.34%	8.26%	0.60x	2.28x	Rs1.39 Billion
2021	16.42%	14.81%	0.60x	1.84x	Rs8.34 Billion
2022	26.40%	29.70%	0.54x	1.64x	Rs27.87 Billion
2023	11.19%	11.37%	0.67x	1.47x	Rs2.09 Billion
2024	19.46%	19.74%	0.67x	1.48x	Rs18.77 Billion
2025	18.89%	19.47%	0.62x	1.55x	Rs21.30 Billion

Industry Comparison

This section compares Zydus Lifesciences Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $20,850,962,057
Average return on equity (ROE) among peers: 10.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zydus Lifesciences Limited (ZYDUSLIFE)	Rs280.90 Billion	24.81%	0.67x	$12.44 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$328.12 Million	0.87%	1.65x	$23.77 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.76 Billion	12.24%	2.47x	$421.37 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$13.86 Billion	-0.01%	0.47x	$688.53 Million
Abbott India Limited (ABBOTINDIA)	$9.38 Billion	24.42%	0.47x	$6.62 Billion
Ajanta Pharma Limited (AJANTPHARM)	$37.90 Billion	24.28%	0.32x	$4.83 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$1.15 Billion
Alkem Laboratories Limited (ALKEM)	$75.58 Billion	20.97%	0.52x	$7.35 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$2.65 Billion	25.34%	0.32x	$168.34 Million
Alembic Pharmaceuticals Limited (APLLTD)	$51.90 Billion	11.24%	0.50x	$1.77 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$8.90 Billion	22.59%	2.94x	$9.83 Billion

About Zydus Lifesciences Limited

NSE:ZYDUSLIFE India Drug Manufacturers - Specialty & Generic

Market Cap

$12.44 Billion

Rs1.15 Trillion INR

Market Cap Rank

#1885 Global

#72 in India

Share Price

Rs1143.10

Change (1 day)

-0.51%

52-Week Range

Rs860.60 - Rs1159.00

All Time High

Rs1302.00